Behavioral Neuroscience
Cardiology
Dentistry School
Functional Brain Imaging
General Clinical Research Center (GCRC)
Medical Genetics
Medicine & Endocrinology
Neurology
Neurosurgery
Portland Alcohol Research Center
Primate Center
Psychiatry
Radiology
VA Hospital

Advanced Imaging Research Center


AIRC Users

Following is a partially updated project list supported by AIRC. We have many projects on-going not listed.

Title: Imaging the central nervous system with iron oxide particle MR contrast agents

Superparamagnetic iron oxide nanoparticle MR contrast agents are gaining use in the CNS. The purpose of these studies is to evaluate the imaging characteristics, time course, and neurotoxicity of iron oxide based agents that have shown potential in the CNS, with the goal of characterizing particle delivery, monitoring trafficking of particles and cells, and visualizing intracerebral tumors. These iron oxide-based agents include the laboratory preparation MION-46, the clinically approved agent ferumoxides (Feridex I.V ®), the investigational agent ferumoxtran-10 (Combidex ®), and the new agent ferumoxytol. The agents consist of an iron oxide core with a variable coating that determines cellular uptake and biological half life. On MR scans the iron oxide agents demonstrate hypointense signal drop out at all concentrations on T2-weighted images, but may show hyperintense (bright) signal on T1-weighted images in areas of low concentration. After MR of CNS delivery, the iron oxide particles may be identified at the light and electron microscopic levels, allowing evaluation of their exact location within tissues.

Osmotic BBB disruption is performed to assess transvascular delivery, time course for imaging, and neurotoxicity of the iron oxide contrast agents. After transvascular delivery, transient (1-3 d) T1 enhancement is seen with ferumoxtran-10 or ferumoxytol, while ferumoxides induce long term (28 d) GRET2* signal dropout. Inoculation of the iron oxide compounds into rat brain is performed to assess the distribution, time course, and cellular uptake of the agents. The distribution of T2 signal drop out approximates the histological distribution of iron staining, while the T2* images shows approximately double the apparent area. No pathological brain cell or myelin changes are detected after either intracerebral inoculation or BBB disruption, even 3 months after iron oxide particle administration. Intracerebral tumor models include the LX-1 and CALU6 SCLC metastasis models, and U87 glioblastoma model. Ferumoxtran-10 rapidly enhances the LX-1 model, which correlates with iron staining in cells with macrophage morphology at the tumor margin, but little enhancement is seen with the other models. We hypothesize that tumor imaging requires the presence of imflammatory cells at the tumor margin or in necrotic areas.

Title: Hypothalamic fMRI Response to Nutrients

  • PI: Jonathan Q. Purnell, MD
  • Co-I: Alexander Stevens, PhD
  • Co-I: Michael Cowley, PhD

Nuclei within the hypothalamus and the brain stem integrate inputs from adipose tissue reflecting body fat stores and the gastrointestinal tract reflecting the amount and types of food ingested. These afferent signals trigger changes in food intake and energy expenditure through mechanisms involving both immediate alterations in neuronal cell electrical activity and relatively slower effects mediated via hormone-receptor binding. While these concepts of a central integrative center controlling weight regulation are well studied in animal models, the importance of these findings to humans is less clear. The present study uses fMRI to study hypothalamic signaling in response to nutrients in lean and obese subjects in order to better understand the neurological mechanisms leading to unwanted weight gain as a result of changes in macronutrient content of the diet.

Title: Functional Organization of Posterior Cortex in Blindness

We are using fMRI to study how occipital, temporal and parietal cortical areas that usually are involved in visual processes in sighted people are reorganized in the blind. A growing body of research indicates that blind individuals have greater auditory perceptual abilities than sighted individuals. What is unclear is if these perceptual abilities are related to the reorganization of occipito-temporal brain regions that are involved in visual processing in sighted individuals. We are attempting to determine the extent of these superior auditory abilities and if they relate to the reorganization of occipito-temporal and occipito-parietal pathways by examining the relationship of neural reorganization and auditory processing skills in early and late onset blind individuals as well as sighted controls.

One ongoing project is looking at auditory perceptual consolidation in blind and sighted individuals. Perceptual consolidation refers to the time necessary to form a stable representation of a stimulus that can be used to guide behavior. Another study is examining the role of occipital area in the blind in auditory and somatosensory perception and attention. Ultimately, we hope to learn how developmental factors and experience influence the organization of the brain and how this organization affects perception and cognition.

Brain Imaging Signatures of Acute Withdrawal Susceptibility

  • PI: John Crabbe, PVAMC
  • CoPI: Bob Hitzemann, PVAMC
  • CoPI: Xin Li, AIRC -OHSU

WSP mice have been selectively bred for alleles at withdrawal susceptibility genes to display high alcohol withdrawal convulsions after cessation of chronic ethanol vapor inhalation, and their counterpart genotype, WSR, have been bred to display very attenuated withdrawal. DBA/2J inbred strain mice also show high alcohol withdrawal per accidental fixation of susceptibility genes, and C57BL/6J mice are the comparison inbred strain that shows genetically low withdrawal. Both WSP and DBA/2J mice also show severe withdrawal from sodium pentobarbital, while WSR and C57BL/6J show low pentobarbital withdrawal. These two drug withdrawal phenotypes can be elicited by a single high-dose intraperitoneal injection (4 g/kg ethanol, 20% v/v in saline, or 60 mg/kg pentobarbital in saline, respectively). Withdrawal is usually indexed behaviorally by exacerbation of the handling-induced convulsion, a behavioral response seen 4-24 hr after acute drug administration. We have been approved to study the behavioral consequences of these acute or chronic withdrawal-inducing treatments under protocols at OHSU and the VA for many years.

What is not known is the differential brain basis for the genotype-specific changes in handling convulsion susceptibility. While pharmacological studies have been performed, they have not followed specific brain regions in detail due to the cost in numbers of animals for such studies.

Functional magnetic resonance imaging (fMRI) is a method for localizing brain activity indirectly by monitoring changes in blood flow (BOLD technology). We propose to use the new Advanced Imaging Research Center’s Siemens 3-Tesla MRI magnet to study the temporal pattern of brain activity in mice after acute injection with ethanol or pentobarbital. fMRI requires that animals remain immobile in the fMRI scanner, which they are unlikely to do voluntarily unless severely restrained. Restraint would cause high levels of stress, which would compromise the experiment. Fortunately, the doses of ethanol and pentobarbital that produce acute behavioral withdrawal signs 4-24 hr later also produce clinical anesthesia, starting by 5 min after injection, and lasting until 3-5 hr after injection. After 3-5 hr, depending on the animal’s individual metabolic rate for the drug, brain levels of drug fall below the anesthetic threshold and animals will begin to move.

The proposed experiments will take advantage of the window of anesthesia to acquire repeated images of blood flow between 5 min and recovery from anesthesia. It is presumed that the genotypes that will eventually express high withdrawal (WSP and DBA/2J) will show a different temporal pattern of regional brain activation than the corresponding low-withdrawal genotypes during the anesthetic period. Ten mice per genotype, of either sex, (40 mice total) will be studied following ethanol injection, and an additional 40 mice followed after pentobarbital injection. Mice will be 6-8 weeks of age when tested. Numbers of subjects per group are based on published studies with rats.

We have no experience with this procedure, nor are there any reported studies like this in the literature. Rats have been tested successfully both with and without clinical anesthesia (e.g., after high doses of diazepam). We will use blood oxygenation level-dependent (BOLD) contrast determined by a gradient-echo echo-planar imaging pulse sequence to be determined by Dr. Li. Based on fMRI studies with rat, cerebral blood volume and flow will be determined after injection of a monocrystalline iron oxide nanocolloid (MION) contrast agent given by pulsed tail-vein infusion at an initial dose of 12 mg/kg (Wu et al., Magn Res Med 2002 48:987). The tail vein infusion needle will be left in place during the period of anesthesia and MION delivered as deemed necessary toi enhance MRI signal strength. MION (or the alternative superparamagnetic contrast agent, gadolinium-DTPA, which will be used if MION fails to improve image signal) are non-toxic and are eliminated readily from the blood.

As soon as the animal is visibly moving, which will be apparent from the breakdown in the fMRI signal quality, the animal will be removed from the scanner and quickly euthanized by CO2 asphyxiation (>5 minutes exposure to 70% CO2).

John Crabbe and Bob Hitzemann are affiliated with the Department of Behavioral Neuroscience and with the Portland Alcohol Research Center as well as the Research Service at the Portland VA Medical Center.

Neuropsychiatric Recovery from Methamphetamine Dependence

  • PI: William F. Hoffman, Ph.D., M.D.
  • Co-I: Alexander Stevens, PhD
  • Co-I: Suzanne Mitchell, Ph.D

This project has the principal aim of establishing the cortical basis of a measure of impulsivity (the Delay Discounting task) and assess its utility in the comparison of methamphetamine abusers to non-users. Plan: This study will test the hypothesis that the cognitive performance we have found in methamphetamine abusers (working memory and impulsivity) is related to activation specific brain regions likely to be involved in the performance of those tasks. Specifically, we hypothesize that impulsivity (a preference for immediate over delayed rewards on the Discount Delay task) is related to failure to activate the orbitofrontal cortex and dorsolateral prefrontal cortex. Methods We will study 10 to 20 chronic methamphetamine abusers, who have been abstinent only a short time and a comparable number of controls who have never used illicit drugs. Subjects are interviewed to establish a diagnosis according to DSM-IV criteria and severity of current symptoms on standard rating scales. We use paper and pencil tests to thoroughly characterize the subjects' cognitive abilities and functional magnetic resonance imaging to link the activity of specific brain regions to performance on the Delay Discounting task. Findings to Date: Sixteen normal subjects have been imaged. The data on these subjects establishes that Delay Discounting task activates a cortical network consisting of lateral and dorsolateral prefrontal, anterior cingulate and posterior parietal regions. The left side is activated more than the right. MeSH terms: amphetamine, functional magnetic resonance imaging, cognitive disorder

Title: Prefrontally-mediated memory in Phenylketonuria

  • Local PI: Robert Steiner, MD
  • Overall PI: Desiree White, PhD
  • Co-I: Urick Szumowski, PhD

This study will be conducted to address the following questions: (1) Do children with phenylketonuria (PKU) have memory problems related to the function of specific areas of the brain? (2) Do problems in these aspects of memory worsen as individuals with PKU age? (3) Do problems in the white matter of the brain contribute to memory problems in individuals with PKU?

The following hypotheses will be tested: Children with PKU exhibit impairments in prefrontally-mediated aspects of memory. To achieve this aim, we will evaluate working memory and strategic memory processing in children with early-treated PKU who range from 7 to 18 years of age. Comparisons will be made with a demographically matched group of typically developing children.

Impairments in prefrontally mediated aspects of memory emerge as children with PKU age. To achieve this aim, we will evaluate working memory and strategic memory processing longitudinally. By doing so, we will define the developmental trajectory of prefrontally-mediated aspects of memory at the level of individual children.

White matter abnormalities contribute to impairments in prefrontally-mediated aspects of memory in children with PKU. This aim will be achieved through the use of diffusion tensor imaging (DTI), a neuroimaging technique permitting refined examination of white matter integrity. Dopamine deficiency also will be examined by assessing blood phenylalanine levels and blood phenylalanine:tyrosine ratios. Findings from DTI, phenylalanine levels, and phenylalanine:tyrosine ratios will be examined in relation to our memory findings.

Both PKU and non-PKU children will complete the memory and related ability tests and the MRI at study entry, approximately 2 years following study entry, and approximately 4 years following study entry. Performance on tests of memory and related abilities will be done on children with PKU and they will be compared with the performance of children without PKU over time.